[go: up one dir, main page]

KR920703118A - 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터 - Google Patents

유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터

Info

Publication number
KR920703118A
KR920703118A KR1019920701696A KR920701696A KR920703118A KR 920703118 A KR920703118 A KR 920703118A KR 1019920701696 A KR1019920701696 A KR 1019920701696A KR 920701696 A KR920701696 A KR 920701696A KR 920703118 A KR920703118 A KR 920703118A
Authority
KR
South Korea
Prior art keywords
dna construct
virus
target response
construct
cells
Prior art date
Application number
KR1019920701696A
Other languages
English (en)
Other versions
KR0148782B1 (ko
Inventor
쥴리아나 리스지바쯔
Original Assignee
원본미기재
더 유나이티드 스테이트 오브 어메리카 에즈 리프리젠티드 바이 더 세크리터리 유.에스 디파트먼트 오브 컴머스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 더 유나이티드 스테이트 오브 어메리카 에즈 리프리젠티드 바이 더 세크리터리 유.에스 디파트먼트 오브 컴머스 filed Critical 원본미기재
Publication of KR920703118A publication Critical patent/KR920703118A/ko
Application granted granted Critical
Publication of KR0148782B1 publication Critical patent/KR0148782B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터
[도면의 간단한 설명]
제1도는 HIV-LTR에 의한 다수의 TAR요소를 이용하여 HIV유전자 발현을 세포내에서 억제하는 것에 관한 작동가설을 나타낸다.
제2a도는 다수의 TAR요소의 구성 및 전사체의 예상되는 이차 구조를 나타낸다. B. 플라스미드의 일반 구조를 나타낸다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 텐덤하게 전사되도록 적어도 2개의 표적반응요소에 작동적으로 연결되는 프로모터 및 벡터로 이루어진 DNA 구조체.
  2. 제1항에 있어서, 5 내지 50개의 표적반응요소를 가지는 DNA 구조체.
  3. 제2항에 있어서, 25개의 표적반응요소를 가지는 DNA 구조체.
  4. 제1항에 있어서, 상기 반응요소가 활성반응요소인 DNA 구조체.
  5. 제4항에 있어서, 상기 요소가 tat 활성반응요소인 DNA 구조체.
  6. 제1항에 있어서, 상기 프로모터가 바이러스에서 생긴 생성물에 의해 조절가공한 DNA 구조체.
  7. 제6항에 있어서, 상기 프로모터가 HW-l LTR인 DNA 구조체.
  8. 제6항에 있어서, 상기 벡터가 PCD7인 DNA 구조체.
  9. 제1항에 있어서, 바이러스성 RNA에 특이한 리보짐을 코오드화하는 DNA 단편을 더 포함하는 DNA 구조체.
  10. 제1항에 있어서, 전이지배 네가티브 돌연변이 바이러스성 단백질을 코오드화 하는 DNA단편을 더포함하는 DNA 구조체.
  11. 제10항에 있어서, 상기 단백질이 GAG인 DNA 구조체.
  12. 하나의 표적반응요소에 작동적으로 연결되는 프로모터 및 벡터로 필수적으로 구성되는 DNA 구조체.
  13. (i) 바이러스 감염된 환자로부터 세포를 얻고; (ii) 상기 세포내에 청구범위 제1항 또는 제10항에 의한 구조체를 도입시키고; 그리고 (iii) (ii)단계의 세포를 상기 치료가 실행되는 조건하에서 상기 환자에게 다시 도입시키는 단계로 이루어지는 바이러스성 감염을 치료하는 방법.
  14. 제13항에 있어서, 상기 바이러스가 인간 면역결핍 바이러스(HIV)인 방법.
  15. 제13항에 있어서, 상기 세포가 골수세포 또는 혈액세포인 방법.
  16. 저해가 실행되는 조건하에서 청구범위 제1항 또는 제12항에 의한 상기 구조체를 바이러스에 감염된 세포내에 도입시키는 것으로 이루어진 HlV-1복제를 저해하는 방법.
  17. 제16항에 있어서, 상기 바이러스가 HIV인 방법.
  18. 바이러스로 감염된 세포내에 청구범위 제1항에 의한 구조체를 도입시키고, 여기서 상기 바이러스의 생성물이 상기 요소의 전사를 조절하여 상기 저해를 실행하는 것으로 이루어진 바이러스 복제를 저해하는 방법.
    ※ 참고사항:최초출원 내용에 의하여 공개되는 것임.
KR1019920701696A 1990-01-18 1991-01-16 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터 KR0148782B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46740790A 1990-01-18 1990-01-18
US467,407 1990-01-18
US59629990A 1990-10-15 1990-10-15
US596,299 1990-10-15
US596299 1990-10-15
PCT/US1991/000175 WO1991010453A1 (en) 1990-01-18 1991-01-16 Vector with multiple target response elements affecting gene expression
US467407 1999-12-20

Publications (2)

Publication Number Publication Date
KR920703118A true KR920703118A (ko) 1992-12-17
KR0148782B1 KR0148782B1 (ko) 1998-08-17

Family

ID=27042041

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920701696A KR0148782B1 (ko) 1990-01-18 1991-01-16 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터

Country Status (6)

Country Link
EP (1) EP0511285A4 (ko)
JP (1) JP2746480B2 (ko)
KR (1) KR0148782B1 (ko)
AU (1) AU642959B2 (ko)
CA (1) CA2074188C (ko)
WO (1) WO1991010453A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2752788B2 (ja) * 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US6245560B1 (en) 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
GB9319772D0 (en) * 1993-09-24 1993-11-10 Therexsys Ltd Therapeutic agent
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
AU702266B2 (en) * 1995-08-25 1999-02-18 Regents Of The University Of California, The Chimeric antiviral agents which incorporate Rev binding nucleic acids
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
CN1294631A (zh) * 1998-03-20 2001-05-09 贝尼泰克澳大利亚有限公司 控制基因表达
AU9196798A (en) * 1998-05-04 1999-11-23 Julianna Lisziewicz Chimeric decoy rnas having synergistic anti-hiv activity
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
WO2006088740A2 (en) 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.

Also Published As

Publication number Publication date
EP0511285A4 (en) 1993-05-26
WO1991010453A1 (en) 1991-07-25
AU642959B2 (en) 1993-11-04
JPH05504255A (ja) 1993-07-08
EP0511285A1 (en) 1992-11-04
AU7074091A (en) 1991-08-05
JP2746480B2 (ja) 1998-05-06
CA2074188A1 (en) 1991-07-19
KR0148782B1 (ko) 1998-08-17
CA2074188C (en) 2004-05-11

Similar Documents

Publication Publication Date Title
KR920703118A (ko) 유전자 발현에 영향을 주는 다수의 표적반응요소를 가진 벡터
Harrich et al. TAR independent activation of the human immunodeficiency virus in phorbol ester stimulated T lymphocytes
Montano et al. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes
Corbeau et al. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line
Brown et al. Efficient polyadenylation within the human immunodeficiency virus type 1 long terminal repeat requires flanking U3-specific sequences
Sakuragi et al. Possible role of dimerization in human immunodeficiency virus type 1 genome RNA packaging
Cen et al. Retrovirus-specific packaging of aminoacyl-tRNA synthetases with cognate primer tRNAs
Remm et al. Human papillomavirus type 18 E1 protein is translated from polycistronic mRNA by a discontinuous scanning mechanism
Madsen et al. An exonic splicing silencer downstream of the 3′ splice site A2 is required for efficient human immunodeficiency virus type 1 replication
EP1087017A3 (en) The cytoplasmic inhibition of gene expression
Böhnlein et al. Identification of a U5-specific sequence required for efficient polyadenylation within the human immunodeficiency virus long terminal repeat
KR920703801A (ko) 리보자임 조성물 및 그 사용방법
Belshan et al. Biological characterization of Rev variation in equine infectious anemia virus
KR920703119A (ko) 치료용 리보자임의 조성물 및 그 발현인자
Tajima et al. The region between amino acids 245 and 265 of the bovine leukemia virus (BLV) tax protein restricts transactivation not only via the BLV enhancer but also via other retrovirus enhancers
Wang et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application
Cherrington et al. Upstream sequences and cap proximity in the regulation of polyadenylation in ground squirrel hepatitis virus
Shen et al. Role of stem B, loop B, and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization
Fu et al. Placement of tRNA primer on the primer-binding site requires pol gene expression in avian but not murine retroviruses
Deffaud et al. Characterization of an internal ribosomal entry segment in the 5′ leader of murine leukemia virus env RNA
Ogert et al. Mutational analysis of the Rous sarcoma virus DR posttranscriptional control element
Guan et al. Leader sequences downstream of the primer binding site are important for efficient replication of simian immunodeficiency virus
Kessler et al. Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication.
Smits et al. Torovirus non-discontinuous transcription: mutational analysis of a subgenomic mRNA promoter
Lee et al. The gene expression of human foamy virus does not require a post-transcriptional transactivator

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920718

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19920718

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19950731

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19960227

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19950731

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PB0901 Examination by re-examination before a trial

Comment text: Request for Trial against Decision on Refusal

Patent event date: 19960603

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 19951030

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970210

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19971006

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 19980227

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 19970117

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19980530

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19980530

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20010519

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20020523

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20030522

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20040520

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20050520

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20060525

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20060525

Start annual number: 9

End annual number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20080610